These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells. Seeger H; Mueck AO; Lippert TH Int J Clin Pharmacol Ther; 2000 May; 38(5):270-2. PubMed ID: 10839471 [TBL] [Abstract][Full Text] [Related]
3. Regulation of endothelial nitric oxide synthase and endothelin-1 expression by fluvastatin in human vascular endothelial cells. Ozaki K; Yamamoto T; Ishibashi T; Matsubara T; Nishio M; Aizawa Y Jpn J Pharmacol; 2001 Feb; 85(2):147-54. PubMed ID: 11286396 [TBL] [Abstract][Full Text] [Related]
4. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Kosch M; Barenbrock M; Suwelack B; Schaefer RM; Rahn KH; Hausberg M Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044 [TBL] [Abstract][Full Text] [Related]
5. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Hayashi K; Kurokawa J; Nomura S; Kuga Y; Ohkura Y; Kajiyama G Biochim Biophys Acta; 1993 Apr; 1167(2):223-5. PubMed ID: 8466953 [TBL] [Abstract][Full Text] [Related]
6. Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Mueck AO; Seeger H; Wallwiener D Exp Clin Endocrinol Diabetes; 2001; 109(3):181-3. PubMed ID: 11409302 [TBL] [Abstract][Full Text] [Related]
7. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Lopez S; Peiretti F; Bonardo B; Juhan-Vague I; Nalbone G Atherosclerosis; 2000 Oct; 152(2):359-66. PubMed ID: 10998463 [TBL] [Abstract][Full Text] [Related]
8. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Meroni PL; Raschi E; Testoni C; Tincani A; Balestrieri G; Molteni R; Khamashta MA; Tremoli E; Camera M Arthritis Rheum; 2001 Dec; 44(12):2870-8. PubMed ID: 11762948 [TBL] [Abstract][Full Text] [Related]
9. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits. Mitani H; Egashira K; Ohashi N; Yoshikawa M; Niwa S; Nonomura K; Nakashima A; Kimura M Pharmacology; 2003 Jul; 68(3):121-30. PubMed ID: 12784083 [TBL] [Abstract][Full Text] [Related]
10. Effect of an estrogen/statin combination on biochemical markers of endothelial function in human coronary artery cell cultures. Mueck AO; Seeger H; Deuringer FU; Wallwiener D Menopause; 2001; 8(3):216-21. PubMed ID: 11355045 [TBL] [Abstract][Full Text] [Related]
11. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Mussoni L; Banfi C; Sironi L; Arpaia M; Tremoli E Thromb Haemost; 2000 Jul; 84(1):59-64. PubMed ID: 10928471 [TBL] [Abstract][Full Text] [Related]
12. Fluvastatin and fluvastatin extended release: a clinical and safety profile. Asberg A; Holdaas H Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166 [TBL] [Abstract][Full Text] [Related]
13. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Ikeda U; Shimpo M; Ohki R; Inaba H; Takahashi M; Yamamoto K; Shimada K Hypertension; 2000 Sep; 36(3):325-9. PubMed ID: 10988259 [TBL] [Abstract][Full Text] [Related]
14. Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. Xu SZ; Zhong W; Watson NM; Dickerson E; Wake JD; Lindow SW; Newton CJ; Atkin SL J Thromb Haemost; 2008 Apr; 6(4):692-700. PubMed ID: 18221360 [TBL] [Abstract][Full Text] [Related]
16. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Sumi D; Hayashi T; Thakur NK; Jayachandran M; Asai Y; Kano H; Matsui H; Iguchi A Atherosclerosis; 2001 Apr; 155(2):347-57. PubMed ID: 11254905 [TBL] [Abstract][Full Text] [Related]
17. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma. Aoki S; Ikeda K; Yamamura M; Kojo S Biol Pharm Bull; 2001 Feb; 24(2):123-6. PubMed ID: 11217077 [TBL] [Abstract][Full Text] [Related]